Corvus Pharmaceuticals (FRA:C17) Moat Score: 3/10 (As of Jul. 06, 2026)


FRA:C17 Corvus Pharmaceuticals Inc FRA:C17
34 GF Score
Price €13.26
! 1 Warning Sign
View Full Analysis

What is Corvus Pharmaceuticals Moat Score?

Corvus Pharmaceuticals FRA:C17 +5.57% 34 Moat Score is 3 as of Jul. 06, 2026. GuruFocus rates FRA:C17 with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,395 Biotechnology companies, Corvus Pharmaceuticals ranks better than 75.56% on this metric.

Corvus Pharmaceuticals has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Corvus Pharmaceuticals has No Moat: Corvus Pharmaceuticals Inc has a weak competitive position in the biotech industry. It lacks substantial market leadership, brand strength, and customer loyalty. While it may possess some intellectual property, the absence of significant regulatory barriers or pricing power limits its moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Corvus Pharmaceuticals might have No Moat - Very weak/transient advantages.

Corvus Pharmaceuticals  (FRA:C17) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Corvus Pharmaceuticals Moat Score Related Terms

FRA:C17 vs LXRX, CGEM, WVE: Moat Score Comparison

For the Biotechnology subindustry, Corvus Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corvus Pharmaceuticals Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corvus Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where Corvus Pharmaceuticals's Moat Score falls into.


FRA:C17
34GF Score
Corvus Pharmaceuticals Inc FRA:C17
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Corvus Pharmaceuticals (FRA:C17) has a Moat Score of 3 as of Jul. 06, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Corvus Pharmaceuticals ranks #341 out of 1395 companies in the Biotechnology industry, placing it in the top 24.4%.
Is Corvus Pharmaceuticals' Moat Score too high?
Corvus Pharmaceuticals' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Corvus Pharmaceuticals' value of 3 is 50% above this industry median. Based on the distribution chart, Corvus Pharmaceuticals ranks #341 out of 1395 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Corvus Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Corvus Pharmaceuticals' Moat Score compare to LXRX and CGEM?
According to the Biotechnology industry distribution chart, Corvus Pharmaceuticals ranks #341 out of 1395 companies for Moat Score. This places Corvus Pharmaceuticals in the top 24% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Corvus Pharmaceuticals' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corvus Pharmaceuticals's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corvus Pharmaceuticals's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corvus Pharmaceuticals stock overvalued right now?
Corvus Pharmaceuticals (FRA:C17) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Corvus Pharmaceuticals' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Corvus Pharmaceuticals (FRA:C17), the current Moat Score is 3 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corvus Pharmaceuticals Business Description

Other Exchanges CRVS:USAC17:Germany
Address 901 Gateway Boulevard, Third Floor, South San Francisco, CA, USA, 94080
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
34GF Score

Get the complete analysis for FRA:C17

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.26
Price